Femasys (NASDAQ:FEMY) Given “Buy” Rating at HC Wainwright

Femasys (NASDAQ:FEMY)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $12.00 price objective on the stock.

Separately, Chardan Capital lowered their target price on shares of Femasys from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th.

Femasys Trading Down 3.6 %

Shares of FEMY stock opened at $1.06 on Wednesday. The firm has a fifty day moving average of $1.14 and a 200-day moving average of $1.13. The company has a debt-to-equity ratio of 0.86, a quick ratio of 3.26 and a current ratio of 3.94. Femasys has a 52-week low of $0.73 and a 52-week high of $2.40. The stock has a market cap of $24.27 million, a price-to-earnings ratio of -1.31 and a beta of -2.83.

Femasys (NASDAQ:FEMY) last posted its earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.04). Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%. The firm had revenue of $0.55 million during the quarter, compared to the consensus estimate of $0.40 million. On average, equities research analysts forecast that Femasys will post -0.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Femasys

Hedge funds have recently added to or reduced their stakes in the stock. CM Management LLC grew its holdings in Femasys by 6.3% during the 2nd quarter. CM Management LLC now owns 425,000 shares of the company’s stock worth $484,000 after acquiring an additional 25,000 shares during the last quarter. Aljian Capital Management LLC bought a new stake in Femasys during the 3rd quarter worth about $27,000. Geode Capital Management LLC lifted its position in Femasys by 9.2% during the 3rd quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock valued at $229,000 after purchasing an additional 17,473 shares during the period. Finally, XTX Topco Ltd lifted its position in Femasys by 123.9% during the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after purchasing an additional 18,004 shares during the period. Institutional investors own 65.27% of the company’s stock.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.